Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
Johnson & Johnson (NYSE:JNJ) Faces Shareholder Activism Over Human Rights and Executive Pay Proposals
Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited
Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.